Dear colleagues and friends,
This month I am proud to report that SBP has made significant progress in our mission to improve human health through scientific discovery.
Last week Jerold Chun, M.D., Ph.D., and his team published groundbreaking research that points to a possible new treatment approach for patients with Alzheimer’s disease. And earlier this month an immune therapy co-developed by Carl Ware, Ph.D., and Eli Lilly and Company (Lilly) entered a Phase 1 clinical trial—a promising step forward for people who suffer from autoimmune disease.
More scientific breakthroughs are within our reach following a very successful annual fundraising gala. I want to extend a special thank-you to our trustees and donors who entrust us with their time and resources. The event’s success is a testament to their hard work and commitment to our vision.
Additionally, our scientists and staff engaged with the community as participants in Padres Pedal the Cause, which raises critical funding for local cancer research, and as hosts of our annual scientific symposium, which focused on the growing field of research called epigenetics.
Looking ahead, please join us at our February SBP Insights event, which will feature a scientist, doctor and patient discussing heart disease.
I hope you enjoy this issue.
Kristiina Vuori, M.D., Ph.D.
President
Pauline and Stanley Foster Presidential Chair
